InvestorsHub Logo
Followers 517
Posts 102284
Boards Moderated 2
Alias Born 01/18/2003

Re: None

Thursday, 07/16/2015 9:19:01 AM

Thursday, July 16, 2015 9:19:01 AM

Post# of 11625
$ATNM has reached MTD in Ph 1/2 study for Actimab-A for newly diagnosed AML. Minimal toxicities. 72% CRi. Phase 2 announcement early-Aug

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.